GlassScriptPhysician profile
Gregory V Scott
NPI 1699746735
$606.47
in general payments reported to CMS, 2019-2025
13 companies · $169 in 2025
The $169 reported for 2025 was more than what 77% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.78 · 2021: $28.70 · 2022: $188 · 2023: $104 · 2024: $102 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $374.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $181.23 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Tanabe Pharma America, INC. | $131.92 | 2023-2025 | Radicava |
| Neurocrine Biosciences, INC. | $82.76 | 2025 | |
| Genzyme Corporation | $48.36 | 2022 | |
| Pfizer INC. | $22.28 | 2023 | |
| Inspire Medical Systems, INC. | $21.66 | 2025 | Inspire |
| Amgen INC. | $20.38 | 2024 | Aimovig |
| Otsuka America Pharmaceutical, INC. | $18.83 | 2025 | Rexulti |
| Cala Health, INC. | $18.04 | 2023 | Cala Trio, Cala Kiq |
| Kyowa Kirin, INC. | $17.53 | 2023 | Nourianz |
| Janssen Pharmaceuticals, INC | $15.30 | 2021 | |
| Adamas Pharmaceuticals, INC. | $14.78 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.